Trial 7H-23-1


PhII-232 /NCI 10553: A Phase 2 Study of Darolutamide in Combination with Leuprolide Acetate in Hormone-Therapy Naïve Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer

Type: Treatment
Phase: Phase II
Status: Open to Accrual
Treatments: Other
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Jacob Thomas, M.D.
Other Trial Staff:  Aida Lozada, Coordinator, Sreebharathy Venkatesh, D.M., Sana Mutalib, Coordinator, Anisa Sandin, Coordinator, Andrew Zeng, Coordinator, Thomas Won, Coordinator, Sophia Marmolejo, Coordinator, Sandy Tran, Coordinator, Azucena Vera, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.